These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3207440)

  • 21. Gaps, inexperience, inconsistencies, and overlaps: crisis in the regulation of genetically modified plants and animals.
    Mandal GN
    William Mary Law Rev; 2004 Apr; 45(5):2167-259. PubMed ID: 16329219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The attitudes of religious, environmental, and science policy leaders toward biotechnology.
    Miller JD
    Recomb DNA Tech Bull; 1985 Dec; 8(4):141-64. PubMed ID: 4095277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological products; bacterial vaccines and toxoids; implementation of efficacy review. Final rule and final order.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Jan; 69(2):255-67. PubMed ID: 14968793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding external controls over the commercial introduction of engineered human tissues. Assessing regulatory and liability issues.
    Smith DS
    Clin Plast Surg; 1999 Oct; 26(4):537-48, vii. PubMed ID: 10553211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Licensing veterinary biologics in the United States.
    Espeseth DA
    Dev Biol Stand; 1992; 79():17-25. PubMed ID: 1286752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Aug; 65(167):52016-8. PubMed ID: 11067735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biotechnology: an introduction to recombinant DNA technology and product availability.
    Evens RP; Witcher M
    Ther Drug Monit; 1993 Dec; 15(6):514-20. PubMed ID: 8122286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revisions to the general safety requirements for biological products; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Apr; 63(75):19431-4. PubMed ID: 10178870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
    Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of communicable diseases; apprehension and detention of persons with specific diseases; transfer of regulations. Food and Drug Administration and Centers for Disease Control and Prevention, HHS. Final rule.
    Fed Regist; 2000 Aug; 65(159):49906-9. PubMed ID: 11067729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. United States government regulations affecting aspergilli and their products.
    Schechtman MG
    Biotechnology; 1992; 23():271-96. PubMed ID: 1504602
    [No Abstract]   [Full Text] [Related]  

  • 35. Regulatory considerations for emergency use of non-USDA licensed vaccines in the United States.
    Hill RE; Foley PL; Carr MY; Elsken LA; Gatewood DM; Ludemann LR; Wilbur LA
    Dev Biol (Basel); 2003; 114():31-52. PubMed ID: 14677675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of regulating biotechnology-derived animals in Canada: animal health and food safety considerations.
    Kochhar HP; Evans BR
    Theriogenology; 2007 Jan; 67(1):188-97. PubMed ID: 17097725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delegations of authority and organization; Ryan White Comprehensive AIDS Resources Emergency Act of 1990--FDA. Final rule.
    Fed Regist; 1991 Aug; 56(167):42527. PubMed ID: 10113840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.